Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocular hypotensive effects of topical versus sublingual brimonidine
IRCT20240217061030N2Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of brimonidine in Glaucoma (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Change in intraocular pressure (IOP). Started Nov 2024; status: completed.
02
Drugs
brimonidine
03
Conditions
Glaucoma
Beyond the preview
Go deeper on IRCT20240217061030N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240217061030N2.